{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:56Z","timestamp":1794273896845,"version":"4.9.0"},"reference-count":30,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Viridian Therapeutics, Inc"},{"name":"Viridian Therapeutics, Inc"},{"DOI":"10.13039\/100002608","name":"American Thyroid Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/19420862.2025.2585616","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T07:04:17Z","timestamp":1763449457000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease"],"prefix":"10.1080","volume":"17","author":[{"given":"Rachel","family":"Kaplan","sequence":"first","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Tsai","sequence":"additional","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Swanson","sequence":"additional","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Foster","sequence":"additional","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-5451","authenticated-orcid":false,"given":"Vahe","family":"Bedian","sequence":"additional","affiliation":[{"name":"Viridian Therapeutics, Inc","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70276-4"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac252"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad213"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000132"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0716"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0097-2"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.013"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0943-8"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1771"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.10.002"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.4397"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/08916939309014643"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3566"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1315"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaf009"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101223"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12564-0"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2082"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470292549.ch11"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.5.3281"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000765"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac415"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020383"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202052"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25234"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.8.26"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1576"},{"key":"e_1_3_7_30_1","volume-title":"Abstract presented at: 51st annual meeting of the North American Neuro-Ophthalmology Society","author":"Cockerham K","year":"2025","unstructured":"Cockerham K, Tang R, Mandeville J, et al. Thrive and Thrive-2 phase 3 trials: efficacy and safety at 15\u00a0weeks of veligrotug (VRDN-001), a full antagonist antibody to IGF-1R, in thyroid eye disease. Abstract presented at: 51st annual meeting of the North American Neuro-Ophthalmology Society; 2025 Mar 15\u201320; Tucson (AZ)."},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202314"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2025.2585616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:46:53Z","timestamp":1765453613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2025.2585616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/19420862.2025.2585616"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2025.2585616","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2585616"}}